nAV-102
Huntington's Disease and Parkinson's Disease
Key Facts
About nVector
nVector is a private, pre-clinical stage biotech firm founded in 2016, operating at the intersection of drug delivery and viral technology. The company's primary asset is its proprietary GreenGlia™ AAV platform, featuring a library of over 10 million capsid variants engineered for superior targeting and distribution within the brain and spinal cord. In addition to its internal therapeutic pipeline targeting neurodegenerative diseases, nVector offers platform licensing and custom capsid engineering services to partners, alongside a biomarker testing and development service led by industry veterans. The company appears to be pre-revenue, focusing on platform validation and partnership development to advance its technologies and programs.
View full company profile